HRP20040939A2 - Treatment of gastroparesis - Google Patents

Treatment of gastroparesis

Info

Publication number
HRP20040939A2
HRP20040939A2 HRP20040939A HRP20040939A2 HR P20040939 A2 HRP20040939 A2 HR P20040939A2 HR P20040939 A HRP20040939 A HR P20040939A HR P20040939 A2 HRP20040939 A2 HR P20040939A2
Authority
HR
Croatia
Prior art keywords
glp
val8
compound
gastroparesis
use according
Prior art date
Application number
Other languages
English (en)
Croatian (hr)
Inventor
Joseph Anthony Jakubowski
Thurman Dwight Mckinney
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HRP20040939A2 publication Critical patent/HRP20040939A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HRP20040939 2002-04-10 2003-03-27 Treatment of gastroparesis HRP20040939A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37165002P 2002-04-10 2002-04-10
PCT/US2003/008457 WO2003087139A2 (en) 2002-04-10 2003-03-27 Treatment of gastroparesis

Publications (1)

Publication Number Publication Date
HRP20040939A2 true HRP20040939A2 (en) 2004-12-31

Family

ID=29250714

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20040939 HRP20040939A2 (en) 2002-04-10 2003-03-27 Treatment of gastroparesis

Country Status (18)

Country Link
US (1) US20050164925A1 (OSRAM)
EP (1) EP1496924A4 (OSRAM)
JP (1) JP2005530732A (OSRAM)
KR (1) KR20040098063A (OSRAM)
CN (1) CN1735423A (OSRAM)
AU (1) AU2003220403A1 (OSRAM)
BR (1) BR0308904A (OSRAM)
CA (1) CA2480858A1 (OSRAM)
EA (1) EA200401345A1 (OSRAM)
EC (1) ECSP045345A (OSRAM)
HR (1) HRP20040939A2 (OSRAM)
IL (1) IL164266A0 (OSRAM)
MX (1) MXPA04009929A (OSRAM)
NO (1) NO20044815L (OSRAM)
NZ (1) NZ535684A (OSRAM)
PL (1) PL373658A1 (OSRAM)
WO (1) WO2003087139A2 (OSRAM)
ZA (1) ZA200408111B (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US8792985B2 (en) 2003-07-21 2014-07-29 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
JP4949838B2 (ja) * 2003-09-19 2012-06-13 ノヴォ ノルディスク アー／エス 新規ｇｌｐ−１誘導体
WO2005028516A2 (en) * 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
WO2006018851A2 (en) 2004-08-18 2006-02-23 Metacure Ltd. Monitoring, analysis, and regulation of eating habits
US9821158B2 (en) 2005-02-17 2017-11-21 Metacure Limited Non-immediate effects of therapy
US9339190B2 (en) 2005-02-17 2016-05-17 Metacure Limited Charger with data transfer capabilities
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
AU2006224537A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended GLP-1 compounds
ATE533403T1 (de) * 2005-03-24 2011-12-15 Metacure Ltd Drahtlose leitungen für magen-darm-trakt- anwendungen
WO2007080595A2 (en) 2006-01-12 2007-07-19 Metacure N.V. Electrode assemblies, tools, and methods for gastric wall implantation
EP1890763A4 (en) 2005-06-02 2017-05-03 Metacure Limited Gi lead implantation
US8442841B2 (en) * 2005-10-20 2013-05-14 Matacure N.V. Patient selection method for assisting weight loss
US8295932B2 (en) 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
CA2800389A1 (en) * 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compounds
AU2012203915B9 (en) * 2006-04-20 2014-10-09 Amgen Inc. GLP-1 compounds
EP2150308B1 (en) * 2007-05-09 2018-08-08 MetaCure Limited Analysis and regulation of food intake
US8423130B2 (en) * 2008-05-09 2013-04-16 Metacure Limited Optimization of thresholds for eating detection
CN102112157B (zh) 2008-08-06 2013-05-29 诺沃-诺迪斯克保健股份有限公司 具有延长的体内效能的缀合蛋白
EP2389389B1 (en) 2009-01-22 2015-04-15 Novo Nordisk Health Care AG Stable growth hormone compounds
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
WO2011017554A2 (en) * 2009-08-07 2011-02-10 Mannkind Corporation Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
SI2525834T1 (sl) 2010-01-22 2019-10-30 Novo Nordisk Healthcare Ag Rastni hormoni s podaljšano in vivo učinkovitostjo
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
WO2011092710A2 (en) * 2010-02-01 2011-08-04 Metacure Limited Gastrointestinal electrical therapy
RU2012151296A (ru) 2010-04-30 2014-06-10 Санва Кагаку Кенкюсо Ко., Лтд Пептид для улучшения биостабильности биоактивного вещества и биоактивное вещество, имеющее повышенную биостабильность
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG10201705097PA (en) 2012-12-21 2017-07-28 Sanofi Sa Functionalized exendin-4 derivatives
EP2981282B1 (en) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
CA2283834A1 (en) * 1997-03-31 1998-10-08 James Arthur Hoffmann Glucagon-like peptide-1 analogs
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand

Also Published As

Publication number Publication date
ECSP045345A (es) 2006-04-19
ZA200408111B (en) 2005-10-07
BR0308904A (pt) 2005-05-03
MXPA04009929A (es) 2006-03-10
EP1496924A4 (en) 2007-05-30
KR20040098063A (ko) 2004-11-18
PL373658A1 (en) 2005-09-05
IL164266A0 (en) 2005-12-18
US20050164925A1 (en) 2005-07-28
CA2480858A1 (en) 2003-10-23
JP2005530732A (ja) 2005-10-13
WO2003087139A3 (en) 2004-01-08
WO2003087139A2 (en) 2003-10-23
AU2003220403A1 (en) 2003-10-27
CN1735423A (zh) 2006-02-15
EP1496924A2 (en) 2005-01-19
NZ535684A (en) 2006-03-31
NO20044815L (no) 2005-01-07
EA200401345A1 (ru) 2005-08-25

Similar Documents

Publication Publication Date Title
HRP20040939A2 (en) Treatment of gastroparesis
Maselli et al. Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity
CN1501809B (zh) 应用胰高血糖素样促胰岛肽的长期治疗方案
JP5645339B2 (ja) 摂食行動の修正
JP5792925B2 (ja) 過剰体重を防止または治療するためのオキシンソモジュリン
Feinglos et al. Effects of liraglutide (NN2211), a long‐acting GLP‐1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes
KR101383493B1 (ko) 정신의학적 질환 및 장애를 치료하기 위한 아밀린 및아밀린 효능제
AU2002239384A1 (en) Chronic treatment regimen using glucagon-like insulinotropic peptides
RS67258B1 (sr) Upotreba dugodelujućih glp-1 peptida
KR20040004418A (ko) 위장 운동성 조절을 위한 제약 조성물
Tschöp et al. Seeking satiety: From signals to solutions
BR112020013733A2 (pt) composições e métodos para tratar doenças metabólicas
Yaw Adu-Sarkodie Clinical management of diabetes mellitus in the older adult patient
KR20080106950A (ko) 정신의학적 질환 및 장애를 치료하기 위한 아밀린 및 아밀린 효능제
Gasbjerg et al. Proglucagon-derived peptides: human physiology and therapeutic potential
US20090227493A1 (en) Combined drug for treating diabetes
AU2003262552A1 (en) Use of human growth hormone in multiple system atrophy
TW202506170A (zh) 糖尿病之治療
Näslund et al. Drug targets modulating the gut-appetite-metabolism axis
Gladson DRUG TREATMENT FOR OSTEOPOROSIS
Tan Regulation of metabolism and food intake by enteropancreatic hormones
Bajaj Incretin Hormones-Pathophysiological Basis of Therapeutic Intervention
HK1080010B (en) Modification of feeding behaviour and weight control by oxyntomodulin
AU2007200732A1 (en) Chronic Treatment Regimen Using Glucagon-Like Insulinotropic Peptides

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20060314

Year of fee payment: 4

OBST Application withdrawn